Researchers have developed a new enzyme called celiacase that breaks down gluten proteins before they trigger immune reactions in celiac disease. According to Gram Research analysis, the enzyme destroyed up to 99% of harmful gluten peptides in lab tests and prevented immune responses in human intestinal tissue samples from celiac patients. In mice, it reduced intestinal damage and inflammation caused by gluten. However, this is still early-stage research—human clinical trials haven’t begun yet, so celiac patients should continue following gluten-free diets.
Scientists have created a new enzyme called celiacase that breaks down gluten proteins before they can trigger the immune system in people with celiac disease. According to Gram Research analysis, this engineered enzyme works in the stomach’s acidic environment and can destroy up to 99% of harmful gluten peptides in lab tests. In animal studies, the enzyme reduced intestinal damage, inflammation, and immune reactions caused by gluten. While more human testing is needed, this breakthrough could eventually offer celiac patients an alternative or supplement to strict gluten-free diets, potentially giving them more food freedom.
Key Statistics
A 2026 research study found that the enzyme celiacase reduced harmful gluten peptides by up to 99% in simulated stomach conditions, outperforming previously developed fungal enzymes at breaking down the highly immunogenic 33-mer gluten fragment.
In mouse studies, celiacase reduced villus atrophy, inflammation, and antibody responses to gluten while restoring immune-regulatory markers and healthy gut bacteria, suggesting potential therapeutic benefits for celiac disease patients.
Laboratory testing with intestinal tissue samples from celiac disease patients showed that gluten fragments broken down by celiacase failed to trigger immune cell responses, indicating the enzyme successfully neutralizes the disease-triggering components of gluten.
The Quick Take
- What they studied: Whether a specially designed enzyme could break down gluten proteins that trigger celiac disease before they damage the intestines
- Who participated: Laboratory tests using human intestinal tissue samples from celiac patients, mouse and rat immune cells, and animal models fed gluten
- Key finding: The enzyme celiacase destroyed up to 99% of harmful gluten peptides in simulated stomach conditions and prevented immune reactions in patient tissue samples
- What it means for you: This could eventually become a pill or supplement that lets celiac patients safely eat small amounts of gluten, though it’s still in early testing stages and won’t replace gluten-free diets yet
The Research Details
Researchers engineered a new enzyme called celiacase by modifying a protein from pitcher plants. They tested it in multiple ways: first in test tubes simulating stomach conditions, then with immune cells and actual intestinal tissue from celiac patients, and finally in mice fed gluten. The enzyme was designed to work in the stomach’s acidic environment where digestion begins, and to work alongside pepsin, the stomach’s natural protein-breaking enzyme.
The scientists compared celiacase to other existing enzymes and found it performed better at breaking down gluten proteins. They specifically tested it against the 33-mer peptide, which is one of the most problematic gluten fragments that triggers strong immune reactions in celiac patients. They also tested it on real wheat flour and gliadin (the main gluten protein) to see if it worked on actual food.
This research approach is important because it tests the enzyme at every stage—from basic chemistry to living tissue to whole animals—before considering human use. This step-by-step testing helps ensure safety and effectiveness. Testing with actual patient tissue samples is especially valuable because it shows the enzyme works against real human immune responses, not just in artificial conditions.
The study was published in EMBO Molecular Medicine, a respected scientific journal. The research used multiple testing methods and compared the new enzyme to existing alternatives, which strengthens the findings. However, this is still laboratory and animal research—human clinical trials haven’t been conducted yet, so we don’t know how well it will work in real patients or what side effects might occur.
What the Results Show
The enzyme celiacase successfully broke down gluten proteins in simulated stomach conditions, reducing harmful gluten peptides by up to 99% at certain doses. When researchers tested the enzyme with immune cells and intestinal tissue from celiac patients, the gluten fragments that had been broken down by celiacase no longer triggered immune reactions. This is crucial because the immune system’s reaction to gluten is what causes intestinal damage in celiac disease.
In mice fed gluten, celiacase reduced several markers of celiac disease: it decreased the flattening of intestinal villi (the tiny finger-like structures that absorb nutrients), reduced inflammation, lowered antibody responses against gluten, and restored healthy gut bacteria. The enzyme also helped restore immune-regulatory markers, which are proteins that help calm down the immune system’s overreaction.
The enzyme worked best at stomach pH levels and actually worked better when combined with pepsin, the stomach’s natural enzyme. This is important because it means celiacase could work as part of the normal digestive process rather than fighting against it. The enzyme also resisted being broken down by pepsin, meaning it stayed active long enough to do its job. Additionally, the enzyme helped restore healthy microbial metabolic pathways in the gut, suggesting it might improve overall gut health in celiac patients.
Previous attempts to create enzymes that break down gluten have used proteins from fungi like Aspergillus niger. This new enzyme, derived from pitcher plants, outperformed those fungal enzymes at breaking down gluten peptides. The enzyme is also more stable in acidic stomach conditions than some previous versions, which is a significant improvement for a therapy that needs to work in the stomach.
This research was conducted in laboratories and in animals, not in human patients. We don’t know yet if the enzyme will work as well in real people or what side effects it might cause. The study didn’t test long-term use or different doses in humans. Additionally, the enzyme was tested in mice and rats, which have different digestive systems than humans. Finally, the study doesn’t tell us whether this enzyme could completely replace a gluten-free diet or if it would only allow occasional gluten consumption.
The Bottom Line
This research is promising but preliminary. Celiac patients should continue following a strict gluten-free diet until human clinical trials are completed and the enzyme is approved by regulatory agencies. The enzyme may eventually become a helpful tool, but it’s not ready for use outside of research settings. People with celiac disease should discuss this research with their doctors but not expect it to be available soon.
This research is most relevant to people with celiac disease who struggle with strict dietary restrictions. It may also interest people with non-celiac gluten sensitivity, though the enzyme was specifically designed for celiac disease. Healthcare providers treating celiac patients should be aware of this development. People without celiac disease don’t need to consider this research.
If human trials begin soon, it could take 5-10 years before this enzyme becomes available as a medical treatment. Even then, it would likely be used alongside a gluten-free diet rather than replacing it entirely. Realistic expectations are that this is a long-term development, not an immediate solution.
Frequently Asked Questions
Can people with celiac disease use this enzyme instead of avoiding gluten?
Not yet. This enzyme is still in early research stages with only animal and lab testing completed. Human clinical trials haven’t started, so it’s not approved for medical use. Celiac patients must continue following gluten-free diets until further testing proves safety and effectiveness in people.
How does celiacase work to treat celiac disease?
Celiacase is an enzyme that breaks down gluten proteins in the stomach before they can trigger the immune system. It destroys the specific gluten peptides that cause intestinal damage in celiac disease, preventing the immune reaction that damages the small intestine.
When will this enzyme be available for celiac patients?
This enzyme is years away from becoming available. Human clinical trials haven’t begun yet. If trials start soon and go well, it could take 5-10 years before regulatory approval and availability. Celiac patients should continue current treatment approaches.
What makes this enzyme better than previous gluten-breaking treatments?
Celiacase works better in stomach acid than previous enzymes and outperforms older fungal-based enzymes at breaking down gluten. It also works alongside the stomach’s natural digestive enzymes rather than fighting against them, making it more effective at neutralizing harmful gluten peptides.
Could this enzyme help people with gluten sensitivity who don’t have celiac disease?
This enzyme was specifically designed for celiac disease, which is an autoimmune condition. While it might help others with gluten problems, the research doesn’t address non-celiac gluten sensitivity, so we don’t know if it would be effective for that condition.
Want to Apply This Research?
- Track intestinal symptoms (bloating, pain, fatigue) on a daily scale of 1-10 to establish a baseline. Once the enzyme becomes available in clinical trials, users could monitor whether symptoms improve compared to their baseline measurements.
- Users with celiac disease can use the app to maintain strict gluten-free diet compliance now while staying informed about enzyme therapy developments. Set reminders to read updates about clinical trial progress and discuss findings with their healthcare provider.
- Create a long-term tracking system for symptom patterns and digestive health markers. When enzyme therapy becomes available, users can compare their symptom scores before and after treatment to measure personal effectiveness, while also tracking any new symptoms that might indicate side effects.
This research describes an experimental enzyme therapy that is not yet approved for human use. People with celiac disease should continue following a gluten-free diet and consult with their healthcare provider before making any dietary changes. This article is for informational purposes only and should not be considered medical advice. Do not attempt to obtain or use celiacase outside of approved clinical trials. Always discuss new treatment options with a qualified healthcare professional who understands your individual medical situation.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.